Log in to save to my catalogue

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease i...

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease i...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2539470379

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma

About this item

Full title

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma

Publisher

Durham: Research Square

Journal title

BMC Cancer, 2020

Language

English

Publication information

Publisher

Durham: Research Square

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Background: The clonoSEQ® Assay (Adaptive Biotechnologies Corporation, Seattle, USA) identifies and tracks unique disease-associated immunoglobulin (Ig) sequences by next-generation sequencing of IgH, IgK, and IgL rearrangements and IgH-BCL1/2 translocations in malignant B cells. Here, we describe studies to validate the analytical performance of t...

Alternative Titles

Full title

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2539470379

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2539470379

Other Identifiers

DOI

10.21203/rs.2.23510/v1